AbbVie Inc（ABBV）の決算・業績分析
AbbVie Incの2025年有価証券報告書をAI分析。売上高$61.2B(+8.6%)。営業利益$15.1B。Health Care。
目次
AbbVie Incの2025年度 業績サマリー
AbbVie Inc（証券コード: ABBV）の2025年度決算・業績分析。売上高は$61.2B（前年比+8.6%）。営業利益は$15.1B（前年比+65.0%）。純利益は$4.2B（前年比-1.2%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
AbbVie Incの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- AbbVie achieved $58.1B in revenue (+3.3% YoY) and $11.8B in net income (+2.5% YoY) for FY2024, driven by strong performance from key products like Skyrizi and Rinvoq (XBRL).
- Operating income rose to $18.1B (+1.1% YoY) with a 31.2% operating margin, supported by acquisitions and R&D investments (XBRL).
- The company returned $11.5B to shareholders via dividends ($10.0B) and share repurchases ($1.5B) (XBRL).
- Net debt stood at $54.0B (2.9x EBITDA), reflecting high leverage despite $12.8B in cash reserves (XBRL).
- ROE reached 114.2%, highlighting strong profitability despite a low equity ratio of 7.7% (XBRL).
AbbVie Incの売上高変化の要因
- •Total revenue for FY2024 was $58.1B, reflecting a 3.3% YoY increase. Growth was driven by acquisitions (Cerevel Therapeutics and ImmunoGen) and strong performance from key products like Skyrizi and Rinvoq (10-K). However, segment-specific revenue data is not available in the XBRL data (N/A). The company's reliance on major products (Skyrizi, Humira, Rinvoq) accounted for 47% of FY2024 revenue, highlighting concentration risk (10-K).
AbbVie Incの営業利益変化の要因
- •Gross profit was $10.7B with a 18.4% gross margin. Operating income rose to $18.1B (+1.1% YoY) with a 31.2% operating margin. Net income reached $11.8B (+2.5% YoY) with a 20.4% net margin. EBITDA was $18.9B (32.5% of revenue). R&D expenses totaled $6.5B (XBRL). YoY changes for gross margin and operating margin are not quantified in the provided data (N/A).
AbbVie Incの事業リスクと対応
Patent expiration and competition from generics/biosimilars could reduce revenues, particularly with the loss of Humira exclusivity post-2023 (10-K).
Reliance on major products (Skyrizi, Humira, Rinvoq) accounting for 47% of FY2024 revenue increases vulnerability to market shifts (10-K).
Patent challenges from third parties and government authorities may impact intellectual property rights (10-K).
Increased litigation over patent validity and scope could lead to financial or operational disruptions (10-K).
Regulatory risks, including legislation accelerating generic/biosimilar approvals, threaten revenue from key products (10-K).
AbbVie Incの今後の見通し・業績予想
AbbVie Incの事業内容
AbbVie Inc. is a research-based biopharmaceutical company focused on developing and commercializing advanced therapies for complex diseases, including immunology, oncology, aesthetics, neuroscience, and eye care (10-K). Key products include Humira (a biologic therapy for autoimmune diseases), Skyrizi (an IL-23 inhibitor for psoriasis), and Rinvoq (a JAK inhibitor for rheumatoid arthritis) (10-K). The company operates as a single global segment, leveraging its robust R&D pipeline ($6.5B R&D expense, XBRL) and market-leading products to maintain a competitive edge in therapeutic areas with significant unmet medical needs (10-K).
AbbVie IncのAI業績分析レポート（2024年度）
AbbVie Inc. (ABBV) FY2024 Annual Report Analysis
Highlights
Business Overview
AbbVie is a biopharmaceutical company focused on advanced therapies for complex diseases. Key products include Humira, Skyrizi, and Rinvoq. The company operates as a single global segment, leveraging its R&D pipeline and market-leading products to maintain a competitive edge (10-K).
Revenue Analysis
FY2024 revenue of $58.1B reflects a 3.3% YoY increase, driven by acquisitions and strong performance from Skyrizi and Rinvoq (10-K). However, segment-specific revenue data is not available (N/A). Major products accounted for 47% of FY2024 revenue (10-K).
Profitability Analysis
Gross profit was $10.7B (18.4% margin). Operating income rose to $18.1B (+1.1% YoY) with a 31.2% margin. Net income reached $11.8B (+2.5% YoY) with a 20.4% margin. R&D expenses totaled $6.5B (XBRL). YoY changes for margins are not quantified (N/A).
Balance Sheet Analysis
Total assets: $134.7B, Total Equity: $10.4B (equity ratio: 7.7%). Current ratio: 0.87x. Cash reserves: $12.8B. Net debt: $54.0B (2.9x EBITDA) (XBRL).
Cash Flow Analysis
Operating cash flow: $24.9B, FCF: $24.2B (after $695M CapEx). Investing activities: -$623M (acquisitions). Financing activities: -$24.8B (dividends: $10.0B, buybacks: $1.5B) (XBRL).
Working Capital Analysis
CCC: 79 days, Receivables: 70 days, Inventory: 86 days, Payables: 77 days (XBRL).
Risks
Outlook
Management expects growth in oncology and immunology products, along with R&D investments ($6.5B, XBRL), to drive future results. Acquisitions of Cerevel Therapeutics and ImmunoGen are expected to enhance innovation (10-K). No specific FY2025 guidance is provided (N/A).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 32.8B | 33.3B | 45.8B | 56.2B | 58.1B | 54.3B |
| Operating Income | 6.4B | 13.0B | 11.4B | 17.9B | 18.1B | 12.8B |
| Net Income | 5.7B | 7.9B | 4.6B | 11.5B | 11.8B | 4.9B |
| Total Assets | 89.1B | 150.6B | 146.5B | 138.8B | 134.7B | 135.2B |
| Total Equity | -8.2B | 13.1B | 15.4B | 17.3B | 10.4B | 3.3B |
| Operating Cash Flow | 13.4B | 13.3B | 17.6B | 22.8B | 24.9B | 22.8B |
Health Careの企業一覧
AbbVie Incと同じ「Health Care」セクターの企業